Anixa Biosciences, Inc.
ANIX
$3.30
-$0.11-3.23%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.16% | -7.69% | -18.85% | 17.48% | -5.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.18% | -13.38% | -6.18% | 3.67% | 26.30% |
| Operating Income | 32.18% | 13.38% | 6.18% | -3.67% | -26.30% |
| Income Before Tax | 31.22% | 11.54% | 2.34% | -7.06% | -30.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.22% | 11.54% | 2.34% | -7.06% | -30.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -42.11% | -43.90% | -17.14% | -3.23% | 2.70% |
| Net Income | 31.10% | 11.12% | 2.18% | -7.17% | -30.51% |
| EBIT | 32.18% | 13.38% | 6.18% | -3.67% | -26.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 32.00% | 11.99% | 4.44% | -3.58% | -26.02% |
| Normalized Basic EPS | 31.97% | 11.64% | 4.35% | -3.54% | -26.49% |
| EPS Diluted | 32.00% | 11.99% | 4.44% | -3.58% | -26.02% |
| Normalized Diluted EPS | 31.97% | 11.64% | 4.35% | -3.54% | -26.49% |
| Average Basic Shares Outstanding | 1.32% | 0.90% | 2.39% | 3.48% | 3.49% |
| Average Diluted Shares Outstanding | 1.32% | 0.90% | 2.39% | 3.48% | 3.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |